A Look At Astrana Health’s Valuation As It Updates Investor Presentation For National Platform Expansion

Astrana Health (ASTH) drew fresh attention after updating its investor presentation at the 44th Annual J.P. Morgan Healthcare Conference, outlining its delegated risk and care delivery model across 16 markets and its evolution into a national platform.

See our latest analysis for Astrana Health.

The refreshed presentation coincides with a recent 15.55% 1 month share price return. However, the 1 year total shareholder return of a 13.05% decline and 3 year total shareholder return of a 22.73% decline suggest longer term momentum has been weaker, even as Astrana outlines its broader national ambitions.

If Astrana’s move toward a national platform has caught your attention, it could be a useful moment to compare it with other healthcare stocks that are shaping the sector.

With Astrana trading at US$27.12 and sitting at a discount to analyst targets and an indicated intrinsic value, the key question is whether this gap reflects an undervalued national platform in progress or a market that is already pricing in future growth.

With Astrana Health last closing at US$27.12 against a narrative fair value of US$40.25, the gap between price and implied worth is clear and sets the scene for a closer look at what is driving that view.

Continued transition to full risk, value-based care contracts (now 78% of revenue, up from 60% YoY) is driving recurring, higher-quality revenue streams and improved patient retention, positioning Astrana to benefit from rising demand for coordinated, efficient healthcare as the U.S. population ages. This likely supports both revenue growth and sustainable margin expansion over time.

Read the complete narrative.

Curious what kind of revenue mix, margin profile, and earnings power sit behind that fair value and discount rate of 7.33%? The narrative leans on a full risk model, scaled revenue expectations, and a future earnings multiple that needs to compress from today’s level. Want to see how those moving parts fit together into a single valuation story?

Result: Fair Value of $40.25 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, that story can break if full risk contract conversions stumble, or if reimbursement shifts across Medicare Advantage and Medicaid squeeze already thin margins.

Find out about the key risks to this Astrana Health narrative.

That 32.6% narrative discount and the SWS fair value of US$40.25 lean on future cash flows, but the current P/E of 142.6x tells a very different story. It sits well above the Healthcare industry at 23.3x and the fair ratio of 26.4x, which points to meaningful valuation risk if expectations reset.